Aurobindo Pharma receives Sebi's warning letter over ongoing USFDA audit https://ift.tt/LBotTrZ

Aurobindo Pharma Ltd has received a warning letter from capital markets regulator Sebi for non-disclosure of details related to an ongoing audit of one of its manufacturing units in Hyderabad and observations made by the USFDA.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/OXraUBz
Share:

No comments:

Post a Comment

Search This Blog

Powered by Blogger.

Labels

Unordered List

  • Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
  • Aliquam tincidunt mauris eu risus.
  • Vestibulum auctor dapibus neque.

Pages

Theme Support

Need our help to upload or customize this blogger template? Contact me with details about the theme customization you need.